Suppression of gain-of-function mutant p53 with metabolic inhibitors reduces tumor growth in vivo

Oncotarget. 2016 Nov 22;7(47):77664-77682. doi: 10.18632/oncotarget.12758.

Abstract

Mutation of p53 occasionally results in a gain of function, which promotes tumor growth. We asked whether destabilizing the gain-of-function protein would kill tumor cells. Downregulation of the gene reduced cell proliferation in p53-mutant cells, but not in p53-null cells, indicating that the former depended on the mutant protein for survival. Moreover, phenformin and 2-deoxyglucose suppressed cell growth and simultaneously destabilized mutant p53. The AMPK pathway, MAPK pathway, chaperone proteins and ubiquitination all contributed to this process. Interestingly, phenformin and 2-deoxyglucose also reduced tumor growth in syngeneic mice harboring the p53 mutation. Thus, destabilizing mutant p53 protein in order to kill cells exhibiting "oncogene addiction" could be a promising strategy for combatting p53 mutant tumors.

Keywords: AMPK signaling; cancer metabolism; gain-of-function mutation; oncogene addiction; p53 mutant knock-in mouse.

MeSH terms

  • A549 Cells
  • Animals
  • Cell Line, Tumor
  • Cell Movement / drug effects
  • Cell Proliferation / drug effects
  • Deoxyglucose / administration & dosage*
  • Deoxyglucose / pharmacology
  • Gene Expression Regulation, Neoplastic / drug effects
  • Gene Knock-In Techniques
  • Humans
  • MAP Kinase Signaling System / drug effects
  • Mice
  • Mutation*
  • Neoplasm Metastasis
  • Neoplasms / pathology*
  • Phenformin / administration & dosage*
  • Phenformin / pharmacology
  • Tumor Suppressor Protein p53 / genetics*
  • Xenograft Model Antitumor Assays

Substances

  • Tumor Suppressor Protein p53
  • Deoxyglucose
  • Phenformin